- United States
- /
- Hospitality
- /
- NasdaqGS:DKNG
Is DraftKings (DKNG) Undervalued After Its Q2 Miss And 2026 Outlook Hold?
Q2 earnings miss puts DraftKings stock back in focus
DraftKings (DKNG) is back on investors’ radar after second quarter results showed revenue and earnings below expectations, a move from profit to loss, and a reaffirmed full year 2026 outlook.
The company paired this weaker quarter with a continued push into its predictions product and a broader Super App approach. That combination is drawing attention from investors who are weighing near term profitability against a longer term effort to broaden revenue sources.
See our latest analysis for DraftKings.
DraftKings shares closed at $24.03 on 6 August, with a 1 day share price return of 8.39% as investors reacted to the Q2 miss and reaffirmed 2026 outlook. However, the year to date share price return of 32.61% and 1 year total shareholder return decline of 43.96% show that longer term momentum has been fading as the market reassesses growth and risk around the Super App and predictions push.
If this earnings move has you looking beyond just one stock, it can be helpful to scan other opportunities that are tied to major technology shifts like data, chips, and infrastructure for artificial intelligence. A quick way to do that is to review a focused list of 56 AI infrastructure stocks
Given that DraftKings just swung back to a loss yet still trades near $24 after the post-earnings rebound, do you lean into the pullback now, or wait for a cheaper entry before the Super App and predictions spend ramps further?
Most Popular Narrative: 14.6% Overvalued
DraftKings closed at $24.03, while the most followed narrative on the stock suggests a fair value of $20.97. That gap is small enough that the story behind the numbers starts to matter more than the headline discount or premium.
DraftKings is no longer operating in a market defined only by rapid legalization and consumer adoption, it is entering a phase where regulators are increasingly influencing how the industry operates.
Curious what sits behind that fair value for DraftKings? The narrative leans heavily on a maturing betting market, margin progress, and a profitability path that assumes disciplined execution on the Super App and predictions push without relying on endless new state launches.
Result: Fair Value of $20.97 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear risks to this DraftKings narrative if prediction markets scale faster than expected, or if regulators tighten rules on promotions and advertising.
Find out about the key risks to this DraftKings narrative.
Another view on DraftKings valuation
The user narrative pegs DraftKings at $20.97 and tags the stock as overvalued. Our DCF model points in a very different direction. It suggests the current $24.03 price sits well below an estimated future cash flow value of $93.22, which frames the stock as materially undervalued. Which story do you think better fits the risk you are willing to take?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Mixed messages on valuation and sentiment around DraftKings do not have to leave you on the sidelines. Take a close look at the data, weigh both risk and upside, then decide what fits your approach with the 3 key rewards and 1 important warning sign
Looking for more DraftKings and market ideas?
If DraftKings has you thinking harder about where to put your next dollar, do not stop at a single stock. Use focused screens to quickly surface ideas that better match your risk level and income needs.
- Target steadier price swings and fewer surprises by reviewing 83 resilient stocks with low risk scores that score well on resilience and business stability.
- Zero in on companies that combine quality, cash flow, and attractive pricing through our focused list of 52 high quality undervalued stocks for potential mispriced opportunities.
- Build a cash flow stream for your portfolio by scanning 8 dividend fortresses that offer higher yields with a focus on durability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap.

Happy for the melanoma patients. It is no surprise that other companies moved up too. It's the optionality getting priced in.
There’s a 60% to 85% probability of the vaccine being approved based on historical drug development data. Could be a lot of scrutiny by the FDA due to the novel platform used.
Market might be getting a little ahead of itself here.
About NasdaqGS:DKNG
DraftKings
Operates as a digital sports entertainment and gaming company in the United States and internationally.
Reasonable growth potential and fair value.